热门资讯> 正文

Alvotech利用LOTTE Biologics支持不断增长的生物仿制药产品组合

2026-10-07 04:53

Alvotech (ALVO) announced on Tuesday that it agreed to a long-term deal with LOTTE Biologics to manufacture multiple biosimilar drugs at its Syracuse, New York facility.
The deal adds 40K liters of manufacturing capacity and expands Alvotech’s U.S. production footprint.
The added capacity will support the company's growing biosimilar pipeline and global supply needs, with potential for the partnership to expand.
Moreover, the commercial production will begin after required technology transfer, facility qualification, and regulatory approvals.
Source: Press Release

More on Alvotech

Alvotech (ALVO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alvotech 2026 Q2 - Results - Earnings Call Presentation
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts
FDA approves additional U.S. manufacturing capacity for Simlandi, Alvotech’s biosimilar to Humira
Alvotech wins double upgrade at Barclays on upcoming FDA decision

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。